# MeiraGTx Holdings plc

**MGTX**

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001735438

# None

**No letter**

6 of 13 inputs computable; 7 are required, with a score in every sleeve

| Scoreboard | |
|---|---|
| **Reliability** | 0.87 AUC<br>filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025 |
| **Peer failure rate** | 1.03% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | $120M to $591M assets<br>total assets $244.4M |
| **Standard universe** | inside<br>revenue above $1M and assets above $10M |
| **Warnings** | thin data<br>not computable: distress, fortress balance sheet |
| **Inputs computable** | 6 of 13 |
| **Graded from** | filings received through Mar 30, 2026<br>234 days before the rescan; latest periodic filing 10-Q received Nov 12, 2026 |
| **Last close** | $8.30<br>2026-11-18; market equity $811.2M; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Mar 30, 2026*

We are a vertically integrated, clinical-stage genetic medicines company with a broad pipeline of late-stage clinical programs, including radiation-induced xerostomia, Parkinson's disease and AIPL1-associated retinal dystrophy. Our clinical programs use targeted local delivery of small doses of genetic medicines to treat both inherited and more common conditions with severe unmet need. The successful development of the clinical pipeline is supported by our internal end-to-end manufacturing capabilities.

## The thirteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 15.1** | | | | | | |
| Gross profitability | not computable | 32.8% | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Return on invested capital | not computable | 9.6% | | | | |
| *one or more required annual facts are missing* | | | | | | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | |
|---|---|---|---|---|---|
| Accruals ratio | (26.4%) | (6.7%) | 15.1 | 756 | 2025-12-31 |
| Gross margin stability, five years | not computable | 2.8 pts | | | |
| *five annual gross margins are required; found 0* | | | | | |
| **Solvency, sleeve percentile 73.3** | | | | | |
| Altman Z double-prime | (14.65) | 0.31 | 70.5 | 705 | 2025-12-31 |
| Net debt to EBITDA | not computable | 1.82x | | | |
| *one or more required annual facts are missing* | | | | | |
| Interest coverage | (8.69x) | (3.61x) | 56.2 | 74 | 2025-12-31 |
| Current ratio | 0.75x | 2.68x | 93.2 | 781 | 2025-12-31 |
| **Growth and financing, sleeve percentile 53.2** | | | | | |
| Revenue growth, three-year compound | not computable | 9.6% | | | |
| *four consecutive annual observations are required* | | | | | |
| Free cash flow growth, three-year compound | not computable | 11.1% | | | |
| *current FCF must be positive and base FCF must exceed $100,000* | | | | | |
| Reinvestment rate | not computable | 33.9% | | | |
| *NOPAT must exceed $100,000* | | | | | |
| Asset growth, three years | (8.4%) | 3.2% | 67.2 | 663 | 2025-12-31 |
| Net share issuance, one year | 3.3% | 1.6% | 39.1 | 625 | 2026-03-30 |

## Warnings

*1 of 7 checks triggered; none of them enters the letter*

| Check | Measured |
|---|---|
| Thin data | 6 of 13 grade factors are computable; minimum is 7 |

## What the price implies

*at the 2026-11-18 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | 21.1% | (1.7%) | 63 |
| Distance from 52-week high | (44.4%) | (30.2%) | 37 |
| EBIT to enterprise value | not computable | 0.5% | |
| Free cash flow yield | (6.2%) | 0.6% | 32 |
| Book value to price | 0.26 | 0.29 | 47 |
| Sales to price | 0.10 | 0.36 | 19 |
| Composite equity issuance, five years | 79.2% | 13.5% | 81 |
| Relative strength against the sector, log excess return | 0.02 | (0.19) | 63 |
| Twelve-month failure probability, CHS model | not computable | 0.06% | |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | fail |
| Return on assets improved | pass |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | fail |
| Current ratio improved | fail |
| No new shares issued | fail |
| Gross margin improved | fail |
| Asset turnover improved | pass |
| **Cash, filings, liquidity** | |

| | |
|---|---|
| Cash and equivalents | $184.7M |
| Operating cash flow, four quarters | $1.4M |
| Months of runway | not finite |
| Days since last periodic filing | 7 (10-Q received Nov 12, 2026) |
| Median daily dollar volume, 63 sessions | $8.7M |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | net income | us-gaap:NetIncomeLoss | -$114.2M | 2025-12-31 | 2026-03-30 | 10-K | 26-036494 |
| 2 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$46.4M | 2025-12-31 | 2026-03-30 | 10-K | 26-036494 |
| 3 | assets | us-gaap:Assets | $244.4M | 2025-12-31 | 2026-03-30 | 10-K | 26-036494 |
| 4 | assets | us-gaap:Assets | $269.8M | 2024-12-31 | 2026-03-30 | 10-K | 26-036494 |
| 5 | current assets | us-gaap:AssetsCurrent | $91.8M | 2025-12-31 | 2026-03-30 | 10-K | 26-036494 |
| 6 | current liabilities | us-gaap:LiabilitiesCurrent | $122.6M | 2025-12-31 | 2026-03-30 | 10-K | 26-036494 |
| 7 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$816.2M | 2025-12-31 | 2026-03-30 | 10-K | 26-036494 |
| 8 | operating income | us-gaap:OperatingIncomeLoss | -$106.0M | 2025-12-31 | 2026-03-30 | 10-K | 26-036494 |
| 9 | book equity | us-gaap:StockholdersEquity | -$5.8M | 2025-12-31 | 2026-03-30 | 10-K | 26-036494 |
| 10 | liabilities | us-gaap:Liabilities | $250.2M | 2025-12-31 | 2026-03-30 | 10-K | 26-036494 |
| 11 | interest expense | us-gaap:InterestExpense | $12.2M | 2025-12-31 | 2026-03-30 | 10-K | 26-036494 |
| 12 | revenue | us-gaap:Revenues | $81.4M | 2025-12-31 | 2026-03-30 | 10-K | 26-036494 |
| 13 | revenue | us-gaap:Revenues | $33.3M | 2024-12-31 | 2026-03-30 | 10-K | 26-036494 |
| 14 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $15.9M | 2022-12-31 | 2023-03-14 | 10-K | 23-003674 |
| 15 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $37.7M | 2021-12-31 | 2023-03-14 | 10-K | 23-003674 |
| 16 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $3.8M | 2025-12-31 | 2026-03-30 | 10-K | 26-036494 |
| 17 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$104.5M | 2024-12-31 | 2026-03-30 | 10-K | 26-036494 |
| 18 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $5.0M | 2024-12-31 | 2026-03-30 | 10-K | 26-036494 |
| 19 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$105.4M | 2023-12-31 | 2025-03-13 | 10-K | 25-002867 |
| 20 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $20.2M | 2023-12-31 | 2025-03-13 | 10-K | 25-002867 |
| 21 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$73.1M | 2022-12-31 | 2024-03-15 | 10-K | 24-003309 |
| 22 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $45.0M | 2022-12-31 | 2024-03-15 | 10-K | 24-003309 |
| 23 | depreciation amortization | us-gaap:DepreciationDepletionAndAmortization | $12.5M | 2025-12-31 | 2026-03-30 | 10-K | 26-036494 |
| 24 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | -$114.2M | 2025-12-31 | 2026-03-30 | 10-K | 26-036494 |
| 25 | income tax | us-gaap:IncomeTaxExpenseBenefit | $0 | 2025-12-31 | 2026-03-30 | 10-K | 26-036494 |
| 26 | current assets | us-gaap:AssetsCurrent | $123.5M | 2024-12-31 | 2026-03-30 | 10-K | 26-036494 |
| 27 | current liabilities | us-gaap:LiabilitiesCurrent | $60.8M | 2024-12-31 | 2026-03-30 | 10-K | 26-036494 |
| 28 | assets | us-gaap:Assets | $326.7M | 2023-12-31 | 2025-03-13 | 10-K | 25-002867 |
| 29 | assets | us-gaap:Assets | $318.2M | 2022-12-31 | 2024-03-15 | 10-K | 24-003309 |
| 30 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 81,446,126 | 2026-03-30 | 2026-03-30 | 10-K | 26-036494 |
| 31 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 78,854,936 | 2025-03-09 | 2025-03-13 | 10-K | 25-002867 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.